Literature DB >> 10025376

Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin.

S Denic1.   

Abstract

In advanced skin carcinomas of the head and neck region, the tumor may be unresectable or curative resection or radiation may either fail or produce poor functional and cosmetic results. The goal of this study was to test the ability of preoperative chemotherapy to decrease the extent of needed resection and tumor response. Five patients, three with squamous cell carcinoma and two with basal cell carcinoma, were treated before surgery with three cycles of cisplatin 20 mg/m2 daily for 4 days and bleomycin 20 mg/day for 4 days by continuous infusion every 3 weeks. All patients had advanced cancer in the head and neck region, one had unresectable tumor, two had xeroderma pigmentosum, and one was a 13-year-old child. The history of prior treatments was as follows: radiation therapy (n = 3), systemic chemotherapy (n = 1), surgery (n = 1), and no treatment (n = 1). One patient had complete clinical but not pathologic response, three had partial response, and one had progressive disease. The extent of resection after chemotherapy was dramatically reduced in the patient with a complete response and minimally changed in the patients with partials responses and progressive disease. All patients who underwent surgery became tumor free. Preventable toxicity was symptomatic hypomagnesemia in one patient, reversible elevation of creatinine in one patient, and mild nausea and vomiting in three patients. With this report, the total number of patients with nonmelanoma skin cancer who were treated with cisplatin is 68, and their overall response is 80%. Only 16 reported patients were treated with preoperative chemotherapy, and study of this treatment approach to advanced skin cancer should be pursued.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025376     DOI: 10.1097/00000421-199902000-00008

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  15 in total

1.  A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

Authors:  Carol M Lewis; Bonnie S Glisson; Lei Feng; Fiona Wan; Ximing Tang; Ignacio I Wistuba; Adel K El-Naggar; David I Rosenthal; Mark S Chambers; Robert A Lustig; Randal S Weber
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

Review 2.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.

Authors:  Kathryn A Gold; Merrill S Kies; William N William; Faye M Johnson; J Jack Lee; Bonnie S Glisson
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

4.  Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.

Authors:  Daniel R Clayburgh; Neil D Gross; Charlotte Proby; Jade Koide; Melissa H Wong
Journal:  Head Neck       Date:  2012-04-12       Impact factor: 3.147

Review 5.  Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies.

Authors:  Julien Lanoue; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-05-01

Review 6.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Therapy of advanced squamous cell carcinoma of the skin.

Authors:  Claudia Bejar; Eve Maubec
Journal:  Curr Treat Options Oncol       Date:  2014-06

8.  Metastatic Basal cell carcinoma: a case report and review of the literature.

Authors:  Anthony Vu; Donald Laub
Journal:  Eplasty       Date:  2011-04-29

Review 9.  Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.

Authors:  Shalini V Mohan; Anne Lynn S Chang
Journal:  Curr Dermatol Rep       Date:  2014-02-09

Review 10.  Vismodegib: the proof of concept in Basal cell carcinoma.

Authors:  Narjiss Berrada; Siham Lkhoyali; Hind Mrabti; Hassan Errihani
Journal:  Clin Med Insights Oncol       Date:  2014-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.